Latest Tax Refunds News

Orthocell has secured a $3 million R&D tax refund, lifting its cash reserves to nearly $50 million and reinforcing its financial strength as it pushes commercialisation of its nerve repair product Remplir™ across key global markets.

Commonwealth Bank of Australia reported a 5% rise in net profit for the half-year ended December 2025, balancing lending growth with margin pressures and increased technology investment.

A handful of small caps ripped higher, but plenty still slipped even after good news. This week’s biggest moves came from a platform partnership win, a reinstated stock, and a cash settlement that removed a long-running dispute.

Delorean Corporation has completed the $53 million Yarra Valley Water bioenergy facility and progressed key projects in South Australia and Victoria, supported by strong government grants and renewable gas policies.

Australian Rare Earths Limited (ASX – AR3) has made significant strides in advancing its Koppamurra Rare Earths Project, securing pilot-scale processing at ANSTO’s new facility and raising $6 million post-quarter to fund development. Concurrently, promising uranium targets have been identified at its Overland Project.

Vectus Biosystems is close to finalising a $4.3 million transaction with Canadian biotech XORTX Therapeutics, while actively pursuing licensing opportunities for its anti-fibrotic drug candidates amid cost reductions.

Mithril Silver and Gold Limited reports strong exploration progress at its Copalquin project in Mexico, with resource expansion drilling underway and a new acquisition adding to its portfolio. The company ends the quarter with a robust cash position, setting the stage for an active 2026.

Unith Ltd reports a 17% rise in quarterly cash receipts alongside strategic funding and new technology launches, signalling momentum in its AI-driven digital human platform.

Papyrus Australia has taken a significant step towards commercialisation with a $4.2 million supply contract and the near completion of its Adelaide Rapid Prototyping and R&D Facility.

Prescient Therapeutics has secured a key regulatory milestone with the EMA granting Orphan Drug Designation for PTX-100 to treat cutaneous T-cell lymphoma, while expanding its Phase 2a clinical trial across multiple continents.

Nimy Resources has announced a maiden JORC Inferred Resource for high-grade gallium and rare earth elements at its Mons Project in Western Australia, marking a significant step towards becoming a key supplier in critical minerals.

Sparc Technologies has marked a significant milestone with sustained hydrogen production at its pioneering pilot plant and secured key patents, while also achieving its first commercial sale of graphene additives.